单克隆抗体靶向治疗晚期或转移性结直肠癌研究进展  

Progress of monoclonal antibodies in the treatment of advanced or metastatic colorectal cancer

作　　者：陈昕涛 姚定康 CHEN Xintao;YAO Dingkang(The Fourth Branch of Basic Medical College of Naval Medical University of People′s Liberation Army,Shanghai,200433;Department of Gastroenterology,Changzheng Hospital Affiliated to Naval Medical University of People′s Liberation Army,Shanghai,200003)

机构地区：[1]中国人民解放军海军军医大学基础医学院四大队,上海200433 [2]中国人民解放军海军军医大学附属长征医院消化内科,上海200003

出　　处：《实用临床医药杂志》2020年第6期11-14,共4页Journal of Clinical Medicine in Practice

摘　　要：单克隆抗体可以有效治疗晚期或转移性结直肠癌,能够安全、有效地抑制肿瘤组织的生长与增殖,防止病情的持续恶化和进展。本研究探讨了单克隆抗体在晚期或转移性结直肠癌治疗中的优势,结合相关研究和文献资料,分析抗血管内皮细胞生长因子(VEGF)单克隆抗体、抗表皮生长因子受体(EGFR)单克隆抗体的实际应用效果。The application of monoclonal antibodies can effectively treat advanced or metastatic colorectal cancer,and can safely and effectively inhibit the growth and proliferation of tumor tissues so as to prevent the continuous deterioration and progression of the disease.Based on this,this study explored the superior role of monoclonal antibodies in the treatment of advanced or metastatic colorectal cancer.The practical application effects of anti-vascular endothelial cell growth factor(VEGF)monoclonal antibody and anti-epidermal growth factor receptor(EGFR)monoclonal antibody were analyzed combined with relevant research and literature.

关 键 词：单克隆抗体 结直肠癌 靶向治疗 抗血管内皮细胞生长因子 抗表皮生长因子受体 转移 

分 类 号：R735.3[医药卫生—肿瘤]